ADMA Biologics is trading at $9.77, up 4.10%; the reason for the September 28 gain remains unclear.
- The company’s investor-relations releases list no release dated September 28; the latest listed release is dated August 5.
- Major U.S. indices were lower, so the supplied market context does not explain the stock’s gain in the same direction.